-
公开(公告)号：US5891622A
公开(公告)日：1999-04-06
申请号：US28543
申请日：1998-02-24
CPC分类号： G01N33/88
摘要： A method to assess oxidative stress in vivo by measuring the amount of free, esterified and glucuronidated forms of isoprostanes (8EPGF2) in a biological sample which contains the isoprostanes is disclosed. The method further includes determining the amount of total isoprostanes present in the sample. This amount is compared with a control sample. The oxidative stress is determined through the comparison wherein the amount of isoprostanes increase in the sample isolated from an organism undergoing oxidative stress compared to the control. Alternatively the method of the present invention provides for only the measurement of the glucuronidated form wherein the amount of glucuronidated isoprostanes increase in the sample isolated from an organism undergoing oxidative stress compared to the control.
摘要翻译： 公开了一种通过测量包含异前列烷烷的生物样品中游离，酯化和葡糖醛酸化形式的异前列烷（8EPGF2）的量来评估体内氧化应激的方法。 该方法还包括测定样品中存在的总异前列烷烷的量。 将该量与对照样品进行比较。 通过比较确定氧化应激，其中与对照相比，从经历氧化应激的生物体分离的样品中异前列烷的量增加。 或者，本发明的方法仅提供葡萄糖醛酸化形式的测量，其中与对照相比，从与经历氧化应激的生物体分离的样品中葡萄糖醛酸化的异前列烷的量增加。
-
公开(公告)号：US11519922B2
公开(公告)日：2022-12-06
申请号：US16259499
申请日：2019-01-28
申请人： Hyesook Kim
发明人： Hyesook Kim
IPC分类号： G01N33/92 , G01N33/68 , G01N33/573
摘要： This invention discloses diagnosis of risk of chemotherapy-induced cardiotoxicity by measurement of increased expression of soluble epoxide hydrolase in vitro and in vivo in cells, tissues or animals including measurement of increased levels of soluble epoxide hydrolase metabolites, e.g., 14,15-DHET and 11,12-DHET, in biological fluids. This invention also includes diagnosis of risk of chemotherapy-induced cardiotoxicity by measuring increased levels of oxidative stress in cells, tissues or animals including measurement of increased levels of oxidative stress biomarkers, e.g., 8-isoprostane, in biological fluids. Fatty acid and protein biomarkers to diagnose the risk of chemotherapy-induced cardiotoxicity are detected using various detection methods including mass spectrometry and immunoassay such as ELISA, Western blot analysis or label-free microwell and nanowell technologies. This invention discloses targeted medical intervention for a subject who is at risk or with chemotherapy-induced cardiotoxicity by treating with soluble epoxide hydrolase inhibitor(s) with or without antioxidants to prevent or ameliorate the chemotherapy-induced cardiotoxicity.
-
3.发明申请FORM-SPECIFIC ANTIBODIES FOR NAG-1 (MIC-1, GDF-15), H6D AND OTHER TGF-BETA SUBFAMILY AND HEART DISEASE AND CANCER DIAGNOSES 审中-公开用于NAG-1（MIC-1，GDF-15），H6D和其他TGF-β亚型亚型和心脏疾病和癌症诊断的形态特异性抗体公开(公告)号：US20160115224A1
公开(公告)日：2016-04-28
申请号：US14966371
申请日：2015-12-11
申请人： Hyesook Kim , Alan Dombkowski
发明人： Hyesook Kim , Alan Dombkowski
IPC分类号： C07K16/22 , G01N33/574 , C07K16/30
CPC分类号： C07K16/22 , C07K16/3069 , C07K2317/10 , C07K2317/33 , C07K2317/34 , G01N33/574 , G01N33/57407 , G01N33/57488 , G01N2333/495 , G01N2333/96433
摘要： A method of producing form-specific anti-peptide antibodies for a wild type protein and its one amino acid mutated protein using a peptide antigen, by obtaining a protein sequence of the wild type protein and its one amino acid mutated protein, selecting a continuous amino acid sequence without any internal cysteine residues that includes the one amino acid mutated sequence and wild type sequence corresponding to the mutated site at the end of the sequence to obtain a synthetic mutation peptide and a synthetic wild type peptide, conjugating the synthetic peptides to a carrier protein, and immunizing an animal to produce antibodies. Methods of detecting cancer and methods of treating cancer.
摘要翻译： 通过获得野生型蛋白质及其一种氨基酸突变蛋白质的蛋白质序列，使用肽抗原制备野生型蛋白质及其一种氨基酸突变蛋白质的形式特异性抗肽抗体的方法，选择连续氨基酸 没有任何内部半胱氨酸残基的酸序列，其包括对应于序列末端的突变位点的一个氨基酸突变序列和野生型序列，以获得合成突变肽和合成的野生型肽，将合成肽与载体 蛋白质，并免疫动物产生抗体。 检测癌症的方法和治疗癌症的方法。
-
公开(公告)号：US08409821B2
公开(公告)日：2013-04-02
申请号：US12716570
申请日：2010-03-03
IPC分类号： G01N33/53 , G01N33/531 , G01N33/532 , C12Q1/48 , C07K16/00
CPC分类号： G01N33/88 , G01N2800/321
摘要： A method of assessing arachidonic acid (AA) metabolites-dependent hypertension by measuring glucuronidated dihydroxyeicosatrienoic acids (DHETs) and DHET metabolites in a biological sample which contains the epitopes unique to DHET (using any methods including GC/MS, LC/MS or ELISA). An example of the glucuronidated DHET metabolite is DHET-alcohols such as omega or omega-1 oxidated DHET and DHET esterified glycerol. The method further includes determining the amount of glucuronidated molecules containing a DHET-specific epitope which is immunoreactive with antibodies produced against DHETs.
摘要翻译： 通过测量包含DHET特有的表位的生物样品中的葡糖苷酸化二羟基二十碳三烯酸（DHET）和DHET代谢物来评估花生四烯酸（AA）代谢物依赖性高血压的方法（使用任何方法，包括GC / MS，LC / MS或ELISA） 。 葡萄糖醛酸化的DHET代谢物的实例是DHET-醇，例如ω或ω-1氧化的DHET和DHET酯化甘油。 该方法还包括确定含有针对DHET产生的抗体具有免疫反应性的DHET特异性表位的葡糖醛酸化分子的量。
-
5.发明申请Chip Production, Hybridization and Data Interpretation for Antibody and Protein Microarrays 有权芯片生产，抗体和蛋白质微阵列的杂交和数据解释公开(公告)号：US20080058215A1
公开(公告)日：2008-03-06
申请号：US10593412
申请日：2005-03-18
CPC分类号： G01N33/54366 , G01N33/54306 , G01N33/573 , G01N2333/90245
摘要： An antibody microarray screen including a substrate, monoclonal and polyclonal antibodies that are purified immunoglobins, wherein the antibodies are spotted on predetermined positions on the substrate, and fluids unprocessed for immunoglobulin isolation (e.g., anti-sera, ascites fluids, or hybridoma culture media), wherein the unprocessed fluids are spotted on the predetermined positions on the substrate. Production of drug-metabolizing enzyme antibody microarrays containing closely related cytochromes P450 is disclosed. Methods of manufacturing an antibody microarray, an internal control molecule for use in an antibody microarray, a method of determining optimal spotting concentrations of IgG and a method to increase a detectable signal with microarray analysis are disclosed.
摘要翻译： 一种包含底物，纯化免疫球蛋白的单克隆抗体和多克隆抗体的抗体微阵列筛选，其中所述抗体被点在基底上的预定位置，以及未加工用于免疫球蛋白分离的流体（例如抗血清，腹水或杂交瘤培养基） ，其中未处理的流体被点在基板上的预定位置上。 公开了含有密切相关的细胞色素P450的药物代谢酶抗体微阵列的生产。 公开了制造抗体微阵列的方法，用于抗体微阵列的内部对照分子，确定IgG的最佳点样浓度的方法以及通过微阵列分析增加可检测信号的方法。
-
6.发明申请公开(公告)号：US20200241019A1
公开(公告)日：2020-07-30
申请号：US16259499
申请日：2019-01-28
申请人： Hyesook Kim
发明人： Hyesook Kim
IPC分类号： G01N33/92 , G01N33/68 , G01N33/573
摘要： This invention discloses diagnosis of risk of chemotherapy-induced cardiotoxicity by measurement of increased expression of soluble epoxide hydrolase in vitro and in vivo in cells, tissues or animals including measurement of increased levels of soluble epoxide hydrolase metabolites, e.g., 14,15-DHET and 11,12-DHET, in biological fluids. This invention also includes diagnosis of risk of chemotherapy-induced cardiotoxicity by measuring increased levels of oxidative stress in cells, tissues or animals including measurement of increased levels of oxidative stress biomarkers, e.g., 8-isoprostane, in biological fluids. Fatty acid and protein biomarkers to diagnose the risk of chemotherapy-induced cardiotoxicity are detected using various detection methods including mass spectrometry and immunoassay such as ELISA, Western blot analysis or label-free microwell and nanowell technologies. This invention discloses targeted medical intervention for a subject who is at risk or with chemotherapy-induced cardiotoxicity by treating with soluble epoxide hydrolase inhibitor(s) with or without antioxidants to prevent or ameliorate the chemotherapy-induced cardiotoxicity.
-
公开(公告)号：US07695927B2
公开(公告)日：2010-04-13
申请号：US11378062
申请日：2006-03-17
IPC分类号： G01N33/53 , G01N33/531 , C12Q1/48 , G01N33/532 , C07K16/00
CPC分类号： G01N33/88 , G01N2800/321
摘要： A method to assess arachidonic acid (AA) metabolites-dependent hypertension by measuring glucuronidated dihydroxyeicosatrienoic acids (DHETs) and DHET metabolites in a biological sample which contains the epitopes unique to DHET (using any methods including GC/MS, LC/MS or ELISA) is disclosed. An example of the glucuronidated DHET metabolite is DHET-alcohols such as omega or omega-1 oxidated DHET and DHET esterified glycerol. The method further includes determining the amount of glucuronidated molecules containing a DHET-specific epitope which is immunoreactive with antibodies produced against DHETs. The present invention measuring glucuronidated DHET levels in a biological sample is useful for drug development and monitoring efficiency of drug treatment of a mammal who has AA epoxygenase-, epoxide hydrolase-and/or UDP-glucuronosyl transferase-dependent hypertension.
摘要翻译： 通过测量包含DHET特有的表位的生物样品中的葡糖醛酸二羟基二十碳三烯酸（DHET）和DHET代谢物来评估花生四烯酸（AA）代谢物依赖性高血压的方法（使用任何方法，包括GC / MS，LC / MS或ELISA） 被披露。 葡萄糖醛酸化的DHET代谢物的实例是DHET-醇，例如ω或ω-1氧化的DHET和DHET酯化甘油。 该方法还包括确定含有针对DHET产生的抗体具有免疫反应性的DHET特异性表位的葡糖醛酸化分子的量。 测量生物样品中葡萄糖醛酸化的DHET水平的本发明可用于具有AA环氧化酶，环氧化物水解酶和/或UDP-葡萄糖醛酸转移酶依赖性高血压的哺乳动物的药物治疗的药物开发和监测效率。
-
公开(公告)号：USD492194S1
公开(公告)日：2004-06-29
申请号：US29163158
申请日：2002-06-28
申请人： Hyesook Kim
设计人： Hyesook Kim
-
公开(公告)号：US06534282B2
公开(公告)日：2003-03-18
申请号：US09946644
申请日：2001-09-04
IPC分类号： G01N3353
CPC分类号： C12Q1/26 , C12Q1/34 , G01N33/88 , Y10S435/973 , Y10S436/808 , Y10S436/811 , Y10S436/815 , Y10T436/25 , Y10T436/25875
摘要： A method to assess hypertension by measuring the amount of free and conjugated hydroxyeicosatrienoic acids (DHETs) and metabolites of DHETs, which are metabolites of arachidonic acid (AA) epoxygenases and epoxide hydrolases, in a biological sample which contains the DHETs (using any methods including GC/MS or ELISA) is disclosed. The method further included determining the amount of molecules containing a DHET-specific epitope immunoreactive with antibodies produced against DHETs present in the sample. This amount is compared with a control sample(s). Hypertension is determined through the comparison wherein the amount of increase of free and conjugated DHETs and metabolites of DHETs in the sample isolated from an organism. The present invention also provides a method to assess catalytic activity of AA epoxygenases using immunoassays by subtracting the amounts of NADPH-independent epoxyeicosatriencic acids (EETs) from total (NADPH-dependent+independent) EETs. The present invention also provides a method to decrease hepatic M epoxygenase expression including 2C23 by treatment of rats with a glucocorticoid including dexamethasone.
-
公开(公告)号：US10317409B2
公开(公告)日：2019-06-11
申请号：US14195209
申请日：2014-03-03
申请人： Hyesook Kim , Sohee Kim
发明人： Hyesook Kim , Sohee Kim
IPC分类号： G01N33/53 , G01N33/574 , A61K31/496 , A61K31/7076 , G01N33/50 , A61K31/433
摘要： A method of characterizing the protein O-GlcNAcylation site-specificity of an antibody. A method of detecting or quantitating the expression of site-specific O-GlcNAcylated proteins expressed in cells and biological samples. A method of diagnosing cancer in a host based on the cellular expression of site-specific O-GlcNAcylated proteins. A method of screening anti-cancer compounds according to their ability to increase a level O-GlcNAcylation of oncogene or tumor suppressor proteins. Methods of treating cancer in an animal host by administering compounds that increase a level of O-GlcNAcylated c-myc or p53 in cancer cells. A method of distinguishing subclasses of pancreatic cancer according to the sensitivity of pancreatic cancer cells to an imidazole derivative, and a method of personalized pancreatic cancer treatment delivered according to the sensitivity subclasses.
-
-
-
-
-
-
-
-
-
搜索结果
23 条记录 (耗时 0.023 秒)
